Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia

Department of Neurology, Children's Hospital Boston, MA, USA.
Annals of Neurology (Impact Factor: 11.91). 04/2012; 71(4):539-51. DOI: 10.1002/ana.22696
Source: PubMed

ABSTRACT The most common neurological symptom of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) is early life refractory epilepsy. As previous studies have shown enhanced excitatory glutamatergic neurotransmission in TSC and FCD brains, we hypothesized that neurons associated with these lesions may also express altered γ-aminobutyric acid (GABA)(A) receptor (GABA(A)R)-mediated inhibition.
Expression of the GABA(A)R subunits α1 and α4, and the Na(+)-K(+)-2Cl(-) (NKCC1) and the K(+)-Cl(-) (KCC2) transporters, in human TSC and FCD type II specimens were analyzed by Western blot and double label immunocytochemistry. GABA(A) R responses in dysplastic neurons from a single case of TSC were measured by perforated patch recording and compared to normal-appearing cortical neurons from a non-TSC epilepsy case.
TSC and FCD type IIb lesions demonstrated decreased expression of GABA(A)R α1, and increased NKCC1 and decreased KCC2 levels. In contrast, FCD type IIa lesions showed decreased α4, and increased expression of both NKCC1 and KCC2 transporters. Patch clamp recordings from dysplastic neurons in acute slices from TSC tubers demonstrated excitatory GABA(A)R responses that were significantly attenuated by the NKCC1 inhibitor bumetanide, in contrast to hyperpolarizing GABA(A)R-mediated currents in normal neurons from non-TSC cortical slices.
Expression and function of GABA(A)Rs in TSC and FCD type IIb suggest the relative benzodiazepine insensitivity and more excitatory action of GABA compared to FCD type IIa. These factors may contribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and may justify add-on trials of the NKCC1 inhibitor bumetanide for the treatment of TSC and FCD type IIb-related epilepsy.

Download full-text


Available from: Joseph R Madsen, Aug 27, 2015
  • Source
    • "In this paper we will review the patterns of subunit composition of the main glutamate [í µí»¼-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-Daspartate (NMDA)] and gamma-aminobutyric acid (GABA) receptors during development [7–13]. We will also review the subunit composition of neurotransmitter receptors that mirrors that of the immature brain, facilitating further seizures and the development of pathologic neuronal networks [14] [15] [16] [17] [18] [19] [20] [21]. Finally, we will discuss the novel therapeutic targets that are being revealed by studying the subunit composition of the neurotransmitter receptors and potential therapeutic translation into clinical practice [3] [4] [5] [6] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuronal activity is critical for synaptogenesis and the development of neuronal networks. In the immature brain excitation predominates over inhibition facilitating the development of normal brain circuits, but also rendering it more susceptible to seizures. In this paper, we review the evolution of the subunit composition of neurotransmitter receptors during development, how it promotes excitation in the immature brain, and how this subunit composition of neurotransmission receptors may be also present in the epileptic brain. During normal brain development, excitatory glutamate receptors peak in function and gamma-aminobutiric acid (GABA) receptors are mainly excitatory rather than inhibitory. A growing body of evidence from animal models of epilepsy and status epilepticus has demonstrated that the brain exposed to repeated seizures presents a subunit composition of neurotransmitter receptors that mirrors that of the immature brain and promotes further seizures and epileptogenesis. Studies performed in samples from the epileptic human brain have also found a subunit composition pattern of neurotransmitter receptors similar to the one found in the immature brain. These findings provide a solid rationale for tailoring antiepileptic treatments to the specific subunit composition of neurotransmitter receptors and they provide potential targets for the development of antiepileptogenic treatments.
    BioMed Research International 09/2014; 2014:301950. DOI:10.1155/2014/301950 · 2.71 Impact Factor
  • Source
    • "Many reports indicate that seizures may alter GABA A R signaling in immature and mature periods. Following the report of depolarizing GABA A R responses in human epileptic subiculum (Cohen et al., 2002), multiple studies confirmed or extended these findings that suggest abnormal CCC expression and depolarizing GABA A R in human epileptic tissues (Aronica et al., 2007; Cepeda et al., 2007; Conti et al., 2011; Huberfeld et al., 2007; Jansen et al., 2010; Munakata et al., 2007; Munoz et al., 2007; Palma et al., 2006; Talos et al., 2012a). Several animal studies also indicated that seizures or the epileptic state in adult rodents may lead to re-appearance of depolarizing GABA A R due to either increase in NKCC1 or decrease in KCC2 activity (Benini and Avoli, 2006; Okabe et al., 2002,c 2003; Pathak et al., 2007; Rivera et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Seizures are very common in the early periods of life and are often associated with poor neurologic outcome in humans. Animal studies have provided evidence that early life seizures may disrupt neuronal differentiation and connectivity, signaling pathways, and the function of various neuronal networks. There is growing experimental evidence that many signaling pathways, like GABAA receptor signaling, the cellular physiology and differentiation, or the functional maturation of certain brain regions, including those involved in seizure control, mature differently in males and females. However, most experimental studies of early life seizures have not directly investigated the importance of sex on the consequences of early life seizures. The sexual dimorphism of the developing brain raises the question that early seizures could have distinct effects in immature females and males that are subjected to seizures. We will first discuss the evidence for sex-specific features of the developing brain that could be involved in modifying the susceptibility and consequences of early life seizures. We will then review how sex-related biological factors could modify the age-specific consequences of induced seizures in the immature animals. These include signaling pathways (e.g., GABAA receptors), steroid hormones, growth factors. Overall, there are very few studies that have specifically addressed seizure outcomes in developing animals as a function of sex. The available literature indicates that a variety of outcomes (histopathological, behavioral, molecular, epileptogenesis) may be affected in a sex-, age-, region- specific manner after seizures during development. Obtaining a better understanding for the gender-related mechanisms underlying epileptogenesis and seizure comorbidities will be necessary to develop better gender and age appropriate therapies.
    Neurobiology of Disease 05/2014; 72. DOI:10.1016/j.nbd.2014.05.021 · 5.20 Impact Factor
  • Source
    • "This depolarization was later shown to be related to a down-regulation of KCC2 and, interestingly, the W. Löscher et al. / Neuropharmacology xxx (2012) 1e13 6 Please cite this article in press as: Löscher, W., et al., Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments, Neuropharmacology (2012), interictal activity was dependent on NKCC1 activity as demonstrated by its sensitivity to bumetanide (Huberfeld et al., 2007; see also Munoz et al., 2007; Palma et al., 2006). Recently, a similar alteration recapitulating immature Cl À regulation was observed in neurons of epileptogenic cortical tubers, dysplastic foci with immature properties, from patients with tuberous sclerosis complex (Talos et al., 2012). These observations suggest that changes in the membrane expression of functionally active NKCC1 and KCC2 are implicated in recapitulation of immature-like Cl À transport and depolarizing GABAergic responses in the ''epileptic'' neurons (Fig. 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In cortical and hippocampal neurons, cation-chloride cotransporters (CCCs) control the reversal potential (E(GABA)) of GABA(A) receptor-mediated current and voltage responses and, consequently, they modulate the efficacy of GABAergic inhibition. Two members of the CCC family, KCC2 (the major neuron-specific K-Cl cotransporter; KCC isoform 2) and NKCC1 (the Na-K-2Cl cotransporter isoform 1 which is expressed in both neurons and glial cells) have attracted much interest in studies on GABAergic signaling under both normal and pathophysiological conditions, such as epilepsy. There is tentative evidence that loop diuretic compounds such as furosemide and bumetanide may have clinically relevant antiepileptic actions, especially when administered in combination with conventional GABA-mimetic drugs such as phenobarbital. Furosemide is a non-selective inhibitor of CCCs while at low concentrations bumetanide is selective for NKCCs. Search for novel antiepileptic drugs (AEDs) is highly motivated especially for the treatment of neonatal seizures which are often resistant to, or even aggravated by conventional AEDs. This review shows that the antiepileptic effects of loop diuretics described in the pertinent literature are based on widely heterogeneous mechanisms ranging from actions on both neuronal NKCC1 and KCC2 to modulation of the brain extracellular volume fraction. A promising strategy for the development of novel CCC-blocking AEDs is based on prodrugs that are activated following their passage across the blood-brain barrier. This article is part of a Special Issue entitled 'Epilepsy'.
    Neuropharmacology 06/2012; 69. DOI:10.1016/j.neuropharm.2012.05.045 · 4.82 Impact Factor
Show more